2026/01/04 by Ivanka Batarilo, Mia Slade‐Vitkovic, Lidija Rukavina +7
paper · doi:10.1111/vox.70175
crossref issued 2026/01/04 · crossref published 2026/01/04 · crossref published-online 2026/01/04 · crossref created 2026/01/05 · crossref published-print 2026/03/01 · crossref deposited 2026/03/13 · crossref indexed 2026/07/29
Abstract Background and Objectives This study presents the results and experiences of bacterial testing of blood components (BCs) at the Croatian Institute of Transfusion Medicine during the period 2011–2024. Materials and Methods During the 14‐year period, 74,283 BCs were tested. Among these, 20,231 components (8345 red blood cell concentrates, 5729 platelet concentrates [PCs] and 6157 plasma units) were tested as part of statistical quality control (QC). In addition, 100% bacterial screening was implemented for aphaeresis platelets in November 2019 and for pooled platelets in October 2022 with 17,187 aphaeresis platelets and 36,865 pooled platelets tested by the end of 2024. All pooled platelets were tested using the large‐volume delayed sampling (LVDS) method, whereas 9596 aphaeresis platelets were tested using the two‐step method (from November 2019 to November 2022) and 7591 using LVDS (from November 2022 to December 2024). BCs were sampled and inoculated into both aerobic and anaerobic culture bottles and incubated at 36 ± 1°C for 7 days. Results As part of the statistical QC, 20,231 BCs (5729 PCs) were tested, resulting in a confirmed contamination rate of 0.09% (0.14% for PCs). Since the implementation of universal screening, 54,052 PCs have been examined, with a confirmed positivity rate of 0.18%. The most frequently detected organism was Cutibacterium acnes . Conclusion The confirmed positive rate of bacterial testing in our study and the isolates from positive cultures are comparable to similar studies. Active bacterial screening of BCs, among other measures, remains a critical step for preventing transfusion‐associated bacterial infections.